GlassScriptPhysician profile
Miguel E Martinez
NPI 1851458640
$1,231.35
in general payments reported to CMS, 2019-2025
21 companies · $49.07 in 2025
The $49.07 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $89.38 · 2021: $178 · 2022: $168 · 2023: $192 · 2024: $57.24 · 2025: $49.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.96 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.00 | 2019-2023 | |
| Astellas Pharma US INC | $174.33 | 2019-2023 | |
| Organogenesis INC. | $117.04 | 2022 | |
| Amag Pharmaceuticals, INC. | $58.00 | 2020 | |
| Mayne Pharma Commercial LLC | $49.07 | 2025 | |
| Coopersurgical, INC. | $48.25 | 2019-2022 | |
| Duchesnay USA Incorporated | $43.92 | 2019 | |
| Biogen, INC. | $24.61 | 2019 | |
| Exeltis, USA INC. | $22.94 | 2023 | Slynd |
| Daiichi Sankyo INC. | $22.74 | 2019 | |
| Becton, Dickinson and Company | $19.75 | 2024 | Bd Onclarity |
| Therapeuticsmd, INC. | $19.38 | 2021 | |
| Millicent US INC | $19.29 | 2024 | Intrarosa, Femring |
| Acella Pharmaceuticals, LLC | $18.20 | 2024 | NP Thyroid 60 |
| Vertical Pharmaceuticals, LLC | $16.88 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $15.94 | 2023 | Myfembree |
| Convatec INC. | $14.09 | 2023 | |
| Lupin INC. | $14.06 | 2019 | |
| Myovant Sciences INC. | $12.87 | 2021 | |
| Allergan, INC. | $11.99 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.